Evaluation of SCH51048 in an experimental model of pulmonary aspergillosis.
AUTOR(ES)
Allendoerfer, R
RESUMO
The efficacy of a novel triazole, SCH51048, was assessed with a murine model of pulmonary aspergillosis and was compared with those of SCH39304 and itraconazole. A wide range of doses of SCH51048 (5 to 50 mg/kg of body weight) was evaluated. Mortality was significantly delayed in mice treated with doses of 5 mg of SCH51048 per kg or greater in comparison with mortality in controls (P < 0.05). Both SCH51048 and SCH39304 at higher doses (30 and 50 mg/kg) reduced the number of viable Aspergillus fumigatus organisms in lung tissue (P < 0.05). In the present model, itraconazole neither delayed mortality nor significantly reduced the counts in tissue at the doses used. We conclude that SCH51048 is an effective therapy for murine pulmonary aspergillosis.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=162739Documentos Relacionados
- Efficacy of SCH 39304 in treatment of experimental invasive aspergillosis.
- Efficacy of intravenous itraconazole against experimental pulmonary aspergillosis.
- Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis.
- Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis.
- Bronchoscopy findings in invasive pulmonary aspergillosis.
